What cancer patients need to know about the coronavirus and ways to connect with our experts.
(888) 777-4167
Menu
Close Search Opener

GBM AGILE Trial (Adaptive Global Innovative Learning Environment)

GBM AGILE (Adaptive Global Innovative Learning Environment) is a seamless clinical trial aimed at identifying the most effective therapies for patients with glioblastoma, the most aggressive form of brain cancer. Led by the trial sponsor Global Coalition for Adaptive Research (GCAR), we were the first in the world to enroll a patient in the GBM AGILE Trial.

This next-generation clinical trial program and adaptive platform trial for brain cancer moves away from the traditional, one-size-fits-all approach to clinical trials; it is a major step forward for precision medicine.

Current glioblastoma treatments have been refined — including surgery, radiation and chemotherapy — but in the era of molecular medicine, immunotherapy and targeted therapies, dramatic leaps in outcomes may be more attainable with this clinical trial.

What is the GBM AGILE difference

Traditional clinical trials:

  • Take three to seven years to produce results
  • Cannot be modified once started
  • Study only one treatment against the standard of care

GBM AGILE changes the model by evaluating multiple therapies simultaneously to more efficiently and rapidly identify effective therapies for patients with glioblastoma. Drugs that show initial evidence of benefit to patients will seamlessly transition to a confirmatory stage designed to support drug approval. Drugs that are underperforming are dropped. The intent is to lower the cost, time, and number of patients required to evaluate potential new, effective therapies for patients with glioblastoma.

The efficiency, speed and learning of GBM AGILE allows for rapid discovery of better treatments for patients with glioblastoma. 

GBM AGILE was first conceived in 2015 by an international group of more than 130 clinicians, researchers, biostatisticians, imagers, pathologists, patient advocates, and leaders from government and industry known as the “GBM Knowledge Network.”. One of the first types of tumors studied in the landmark precision medicine effort was glioblastoma. Henry Ford was a major TCGA contributor, nearly 25% of all the gliomas studied over the course of the initiative having been donated by Henry Ford’s Hermelin Brain Tumor Center.

Request Information on Clinical Trials

If you were diagnosed with a brain tumor we may have a clinical trial for you.

Request more information

24 hour appointment guarantee
Call us at (888) 777-4167
Request an Appointment
Close

Schedule Appointment Online

If this is an emergency, call 911 or go to your nearest emergency department.

For your safety, please select a MyChart video visit on demand or call our MyCare Advice Line at 844-262-1949 before scheduling if:

  • You currently have a temperature greater than 100.4 degrees Fahrenheit
  • In the past 21 days, you have been diagnosed with COVID-19
  • In the past 14 days, you have had contact with anyone diagnosed with COVID-19
  • You are experiencing a new loss of taste and/or sense of smell
  • If you have experienced two or more of the following symptoms in the last 3 days:
    • fever
    • chills
    • drenching sweats
    • new cough
    • shortness of breath
    • body aches
    • headache
    • sore throat
    • runny nose or nasal congestion
    • nausea/vomiting/diarrhea

Henry Ford Health System is committed to ensuring our Deaf or hard-of-hearing patients and visitors have equal access to all services. We provide the appropriate auxiliary aids and services, including qualified sign language interpreters, TTYs and other assistive listening devices, at no cost. To request assistance, call 313-916-1896 or email CommunicationAccess@hfhs.org.

Schedule Appointment for